PureTech Health contemplating US listing on Nasdaq
Puretech Health Plc
156.60p
16:30 27/09/24
Clinical-stage biopharmaceutical company PureTech Health announced that it was exploring the potential for a listing of American depository shares (ADS) on Nasdaq in the.
Cboe UK 250
18,690.63
16:29 27/09/24
Cboe UK 250 NTR
27,552.53
16:29 27/09/24
Cboe UK 350
14,741.79
16:29 27/09/24
Cboe UK 350 NTR
24,171.06
16:29 27/09/24
Cboe UK All Companies
14,622.83
16:29 27/09/24
Cboe UK All Companies NTR
24,669.96
16:30 27/09/24
Cboe UK Healthcare Sector
23,283.47
16:30 27/09/24
Cboe UK Healthcare Sector NTR
39,492.55
16:29 27/09/24
The London-listed firm said the ADSs would represent ordinary shares, and would be sold through a registered initial public offering in the US.
It said the US listing would be expected to include an issue of new ordinary shares underlying the ADSs.
The terms of any US listing had not yet been determined, the board said, adding that there could be no assurance as to the timing or completion of any US listing.
“The company intends that the potential US listing would be in addition to the company's premium listing on the Official List of the UK Financial Conduct Authority and trading on the main market of the London Stock Exchange,” PureTech Health explained in its statement.
“A further announcement will be made by PureTech if and when appropriate.”